4.8 Article

Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma

期刊

FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.951529

关键词

m(5)C; immunotherapy; biomarker; drug sensitivity; HCC; precision medicine

资金

  1. National Key R&D Program of China [2018YFC1313300]
  2. National Natural Science Foundation of China [81070362, 81172470, 81372629, 81772627, 81874073, 81974384]
  3. Nature Science Foundation of Hunan Province [2015JC3021, 2016JC2037]
  4. Beijing CSCO Clinical Oncology Research Foundation [Y-HR2019-0182, Y-2019Genecast-043]

向作者/读者索取更多资源

Immunotherapy is a promising anti-cancer strategy in hepatocellular carcinoma (HCC), but there are limited biomarkers for patient selection. The role of methylcytosine (m(5)C) in predicting clinical responses to immunotherapy in HCC has not been fully understood. In this study, we identified a prognostic risk model and two diagnostic models based on m(5)C regulators, which showed promising results in predicting patient outcomes and distinguishing HCC tumors from normal liver tissues.
BackgroundImmunotherapy is a promising anti-cancer strategy in hepatocellular carcinoma (HCC). However, a limited number of patients can benefit from it. There are currently no reliable biomarkers available to find the potential beneficiaries. Methylcytosine (m(5)C) is crucial in HCC, but its role in forecasting clinical responses to immunotherapy has not been fully clarified. MethodsIn this study, we analyzed 371 HCC patients from The Cancer Genome Atlas (TCGA) database and investigated the expression of 18 m(5)C regulators. We selected 6 differentially expressed genes (DEGs) to construct a prognostic risk model as well as 2 m(5)C-related diagnostic models. ResultsThe 1-, 3-, and 5-year area under the curve (AUC) of m(5)C scores for the overall survival (OS) was 0.781/0.762/0.711, indicating the m(5)C score system had an ideal distinction of prognostic prediction for HCC. The survival analysis showed that patients with high-risk scores present a worse prognosis than the patients with low-risk scores (p< 0.0001). We got consistent results in 6 public cohorts and validated them in Xiangya real-world cohort by quantitative real-time PCR and immunohistochemical (IHC) assays. The high-m(5)C score group was predicted to be in an immune evasion state and showed low sensitivity to immunotherapy, but high sensitivity to chemotherapy and potential targeted drugs and agents, such as sepantronium bromide (YM-155), axitinib, vinblastine and docetaxel. Meanwhile, we also constructed two diagnostic models to distinguish HCC tumors from normal liver tissues or liver cirrhosis. ConclusionIn conclusion, our study helps to early screen HCC patients and select patients who can benefit from immunotherapy. Step forwardly, for the less likely beneficiaries, this study provides them with new potential targeted drugs and agents for choice to improve their prognosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据